Intensity Therapeutics, Inc. announced on May 29, 2025, that its Phase 3 INVINCIBLE-3 clinical trial for metastatic soft tissue sarcomas has been selected for a 'Trials in Progress' poster presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The presentation will take place from May 30 to June 5, 2025, in Chicago. Dr. Sant P. Chawla will present the poster, which outlines the study protocol.
The INVINCIBLE-3 trial is evaluating INT230-6 as a monotherapy compared to standard of care systemic chemotherapy, with overall survival as the primary endpoint. Prior Phase 1/2 data in refractory, metastatic sarcoma patients showed a disease control rate of 93% and a median overall survival of 21.3 months.
Lewis H. Bender, Intensity Therapeutics' CEO, noted that eight regulatory agencies, including the U.S. FDA, have authorized the Phase 3 study. However, new enrollment for the Phase 3 trial has been paused until sufficient additional funding is obtained, though enrolled patients continue to receive treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.